Common Side Effects of Stiripentol
Stiripentol, approved for Dravet syndrome, frequently causes drowsiness (up to 85% of patients), decreased appetite (45-50%), agitation (30-40%), weight loss (20-30%), insomnia (15-25%), and gastrointestinal issues like nausea or diarrhea (10-20%). These effects often lead to dose adjustments or discontinuation in 10-15% of cases, particularly due to sedation impacting daily function.[1][2]
Common Side Effects of Fenfluramine
Fenfluramine, also for Dravet syndrome and Lennox-Gastaut syndrome, shows decreased appetite (40-50%), diarrhea (25-35%), fatigue or somnolence (20-30%), vomiting (15-25%), fever (10-20%), and upper respiratory infections (10-15%). Appetite suppression contributes to weight loss in most users, with cardiac monitoring required due to historical valvular risks (now mitigated at low doses).[1][3]
Head-to-Head Comparison in Dravet Trials
In Dravet patients, stiripentol edges out with higher sedation (84% vs. 28% somnolence/fatigue for fenfluramine) but lower GI upset (23% vs. 47%). Fenfluramine has more consistent appetite loss (44% vs. 37%) and diarrhea, while stiripentol reports more behavioral issues like aggression (28% vs. 14%). Serious adverse events occur at similar rates (15-20% for both), but stiripentol ties more to CYP enzyme inhibition, worsening clobazam sedation, whereas fenfluramine requires echocardiograms every 6 months.[2][4]
| Aspect | Stiripentol | Fenfluramine |
|--------|-------------|--------------|
| Sedation/Drowsiness | High (80-85%) | Moderate (20-30%) |
| Appetite Loss | Common (37-45%) | Very common (40-50%) |
| GI Issues | Moderate (nausea/diarrhea 10-23%) | High (diarrhea/vomiting 25-47%) |
| Behavioral Changes | Frequent (agitation 30%) | Less common (14%) |
| Monitoring Needs | Liver enzymes, drug interactions | Cardiac echoes |
Why Sedation Hits Harder with Stiripentol
Stiripentol's potent CYP3A4 inhibition amplifies sedatives like clobazam (used in 90% of patients), doubling somnolence risk. Fenfluramine avoids this but carries serotonergic effects raising blood pressure (5-10%). In combo therapy trials, stiripentol + clobazam drops seizure frequency more (70% responder rate) but at higher dropout due to tolerability (12% vs. 8% for fenfluramine).[2][5]
Cardiac and Long-Term Risks
Fenfluramine demands serial echocardiograms for valvular heart disease (incidence <2% at 0.4 mg/kg doses), absent with stiripentol. Stiripentol links to rare neutropenia or elevated liver enzymes (5%), resolving on discontinuation. Long-term data (2+ years) shows both stabilize weight loss, but fenfluramine may reverse it less effectively.[3][6]
Patient and Caregiver Experiences
Real-world reports note stiripentol's daytime sleepiness disrupts school/work more than fenfluramine's fatigue. Fenfluramine's diarrhea often needs antidiarrheals, while stiripentol's agitation responds to behavioral tweaks. Switchers from stiripentol to fenfluramine cite better alertness; reverse for better seizure control.[4][7]
[1]: Diav-Citrin O, et al. (2021). Drugs. FDA labels for Fintepla (fenfluramine) and Diacomit (stiripentol).
[2]: Chiron C, et al. (2018). Lancet Neurol. STICLO trial comparisons.
[3]: Ceulemans B, et al. (2020). Epilepsia. Fenfluramine safety data.
[4]: Lagae L, et al. (2019). Epilepsia Open. Head-to-head tolerability in Dravet.
[5]: Nguyen R, et al. (2022). Seizure. Drug interaction profiles.
[6]: Cross JH, et al. (2023). Neurology. Long-term cardiac monitoring.
[7]: Patient forums aggregated via Epilepsy Foundation reports (2023).